These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 20163275)

  • 21. Switching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspective.
    Chung SJ; Asgharnejad M; Bauer L; Benitez A; Boroojerdi B; Heidbrede T; Little A; Kim HJ
    Expert Rev Neurother; 2017 Jul; 17(7):737-749. PubMed ID: 28548894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch.
    Högl B; Oertel WH; Stiasny-Kolster K; Geisler P; Beneš H; García-Borreguero D; Trenkwalder C; Poewe W; Schollmayer E; Kohnen R
    BMC Neurol; 2010 Sep; 10():86. PubMed ID: 20920156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug safety evaluation of rotigotine.
    Sprenger FS; Seppi K; Poewe W
    Expert Opin Drug Saf; 2012 May; 11(3):503-12. PubMed ID: 22468676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rotigotine transdermal delivery for the treatment of Parkinson's disease.
    Rascol O; Perez-Lloret S
    Expert Opin Pharmacother; 2009 Mar; 10(4):677-91. PubMed ID: 19239399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study.
    Oertel WH; Benes H; Garcia-Borreguero D; Högl B; Poewe W; Montagna P; Ferini-Strambi L; Sixel-Döring F; Trenkwalder C; Partinen M; Saletu B; Polo O; Fichtner A; Schollmayer E; Kohnen R; Cassel W; Penzel T; Stiasny-Kolster K
    Sleep Med; 2010 Oct; 11(9):848-56. PubMed ID: 20813583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study.
    Garcia-Borreguero D; Allen R; Hudson J; Dohin E; Grieger F; Moran K; Schollmayer E; Smit R; Winkelman J
    Curr Med Res Opin; 2016; 32(1):77-85. PubMed ID: 26569149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study.
    Trenkwalder C; Canelo M; Lang M; Schroeder H; Kelling D; Berkels R; Schollmayer E; Heidbrede T; Benes H
    Sleep Med; 2017 Feb; 30():257-265. PubMed ID: 26896370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rotigotine: the first new chemical entity for transdermal drug delivery.
    McAfee DA; Hadgraft J; Lane ME
    Eur J Pharm Biopharm; 2014 Nov; 88(3):586-93. PubMed ID: 25173087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States.
    Hening WA; Allen RP; Ondo WG; Walters AS; Winkelman JW; Becker P; Bogan R; Fry JM; Kudrow DB; Lesh KW; Fichtner A; Schollmayer E;
    Mov Disord; 2010 Aug; 25(11):1675-83. PubMed ID: 20629075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rotigotine and restless legs syndrome: new indication. The worst dopamine agonist. Just as unsatisfactory; defective design.
    Prescrire Int; 2009 Oct; 18(103):197. PubMed ID: 19882782
    [No Abstract]   [Full Text] [Related]  

  • 31. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome.
    Kenney C; Jankovic J
    Expert Opin Pharmacother; 2007 Jun; 8(9):1329-35. PubMed ID: 17563266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis-Ekbom disease).
    Elshoff JP; Hudson J; Picchietti DL; Ridel K; Walters AS; Doggett K; Moran K; Oortgiesen M; Ramirez F; Schollmayer E
    Sleep Med; 2017 Apr; 32():48-55. PubMed ID: 28366342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine.
    Beneš H; García-Borreguero D; Ferini-Strambi L; Schollmayer E; Fichtner A; Kohnen R
    Sleep Med; 2012 Jun; 13(6):589-97. PubMed ID: 22503658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-to-severe restless legs syndrome.
    Sun Y; van Valkenhoef G; Morel T
    Curr Med Res Opin; 2014 Nov; 30(11):2267-78. PubMed ID: 25050588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post Hoc Analysis of Data from Two Clinical Trials Evaluating the Minimal Clinically Important Change in International Restless Legs Syndrome Sum Score in Patients with Restless Legs Syndrome (Willis-Ekbom Disease).
    Ondo WG; Grieger F; Moran K; Kohnen R; Roth T
    J Clin Sleep Med; 2016 Jan; 12(1):63-70. PubMed ID: 26446245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relation of the International Restless Legs Syndrome Study Group rating scale with the Clinical Global Impression severity scale, the restless legs syndrome 6-item questionnaire, and the restless legs syndrome-quality of life questionnaire.
    Allen R; Oertel W; Walters A; Benes H; Schollmayer E; Grieger F; Moran K; Kohnen R
    Sleep Med; 2013 Dec; 14(12):1375-80. PubMed ID: 24246378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rotigotine in the treatment of primary restless legs syndrome: A meta-analysis of randomized placebo-controlled trials.
    Ding J; Fan W; Chen HH; Yan P; Sun SG; Zheng J
    J Huazhong Univ Sci Technolog Med Sci; 2015 Apr; 35(2):169-175. PubMed ID: 25877347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study.
    Inoue Y; Shimizu T; Hirata K; Uchimura N; Ishigooka J; Oka Y; Ikeda J; Tomida T; Hattori N;
    Sleep Med; 2013 Nov; 14(11):1085-91. PubMed ID: 24055212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transdermal rotigotine for the perioperative management of restless legs syndrome.
    Högl B; Oertel WH; Schollmayer E; Bauer L
    BMC Neurol; 2012 Sep; 12():106. PubMed ID: 23009552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany.
    Stiasny-Kolster K; Berg D; Hofmann WE; Berkels R; Grieger F; Lauterbach T; Schollmayer E; Bachmann CG
    Sleep Med; 2013 Jun; 14(6):475-81. PubMed ID: 23668924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.